Information Provided By: 
Fly News Breaks for November 1, 2019
CHE
Nov 1, 2019 | 06:11 EDT
JMP Securities analyst Peter Martin upgraded Chemed to Outperform from Market Perform with a $490 price target. The analyst sees the outlook for hospice reimbursement as "stable" and also expects the labor cost increases to subside. Martin further notes that given the growth of water restoration and commercial services, Chemed's plumbing division should not see the downside in EBITDA that the company experienced during the last recession.
News For CHE From the Last 2 Days
